Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.39 |
| ▸ | BACE1 | P56817 | 2/20 | 0.36 |
| ▸ | PNP | P00491 | 2/20 | 0.36 |
| ▸ | VDR | P11473 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7111074 | 0.90 | PNP (0.44) | ADORA2ABACE1PNPVDRPDE10A | |
| SCHEMBL7120152 | 0.86 | PNP (0.45) | ADORA2ABACE1PNPVDRPDE10A | |
| SCHEMBL6547901 | 0.84 | GAA (0.39) | ADORA2AALOX5APBACE1VDRGAA | |
| SCHEMBL7117280 | 0.84 | PNP (0.45) | ADORA2APNPALDH1A1SMN1; SMN2HIF1A | |
| SCHEMBL7111860 | 0.84 | PNP (0.45) | ADORA2APNPALDH1A1SMN1; SMN2HIF1A | |
| SCHEMBL7113247 | 0.83 | PNP (0.39) | ADORA2ABACE1PNPVDRGAA | |
| SCHEMBL7113866 | 0.83 | PNP (0.39) | ADORA2ABACE1PNPVDRPDE10A | |
| SCHEMBL7110374 | 0.83 | SMN1; SMN2 (0.48) | ADORA2APNPPDE10ASMN1; SMN2 | |
| SCHEMBL7112394 | 0.82 | ADORA2A (0.39) | ADORA2AALOX5APBACE1PNPVDR | |
| SCHEMBL7118322 | 0.82 | PNP (0.39) | ADORA2ABACE1PNPVDRPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030186978-A1 | Novel telomerase inhibitors | PHARMACIA ITALIA, SPA (IT) | 2003-10-02 | — | — | US | claimed |
| US-20030186978-A1 | Novel telomerase inhibitors | PHARMACIA ITALIA, SPA (IT) | 2003-10-02 | — | — | US | disclosed |
| WO-2001096339-A1 | NOVEL TELOMERASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186978-A1 | Novel telomerase inhibitors | TERT, TERF2IP, TERF2 | ADORA2A 4414/4885ALOX5AP 3952/4885BACE1 3523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.